Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Core Insights - Adaptimmune Therapeutics plc will participate in the Guggenheim Securities SMID Cap Biotech Conference on February 6, 2025, highlighting its focus on solid tumor cancer treatment through cell therapy [1][5]. Company Overview - Adaptimmune is a fully integrated cell therapy company aiming to redefine cancer treatment with its engineered T cell receptor (TCR) platform, developing personalized medicines to target and destroy difficult-to-treat solid tumor cancers [3]. Event Details - The conference will feature a fireside chat with CEO Adrian Rawcliffe on February 6 at 3:00 p.m. EST, and the event can be accessed via the company's website, with a replay available post-event [2][5].